ASCO 2018 Roundtable Lung Cancer Potential Showdown of Two Positive Trials Keynote 407 and IMPower 131

ASCO 2018 Roundtable - Lung Cancer - Potential Showdown of Two Positive Trials? Keynote 407 and IMPower 131

18:30 EST 30 Nov 2018 | GRACE
Howard (Jack) West, MD, Founder and President

Drs. H. Jack West, Medical Director - Thoracic Oncology Program at Swedish Cancer Institute, President and CEO of GRACE, Karen Kelly - Associate Director for Clinical Research at UC Davis Comprehensive Cancer Center, and Sandip Patel - Medical Oncologist and Associate Professor of Medicine at Moores Cancer Center, UC San Diego Health, gathered post meeting to discuss new information from ASCO 2018 regarding lung cancer.

In this roundtable video, the doctors discuss the potential showdown of two positive trials -- Keynote 407 - chemo combined with keytruda, and IMPower 131 - combination trial of carboplatin and abraxane alone or combined with tecentriq.

GRACE thanks the following sponsors for their support.

Related Content: 
ASCO 2018 Roundtable - Lung Cancer - Keynote 042 Trial - Keytruda (Pembrolizumab) as a Single Agent Compared to Doublet Chemotherapy for NSCLC
ASCO 2018 Roundtable - Lung Cancer - Keynote189 - Cisplatin or Carboplatin with Alimta & Keytruda - Is this a Practice Changing Approach?
Video Language: 
English

More From BioPortfolio on "ASCO 2018 Roundtable - Lung Cancer - Potential Showdown of Two Positive Trials? Keynote 407 and IMPower 131"